Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells ... of acute myeloid leukemia and ...